Related Experiment Video

Updated: Nov 28, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.7K

Budget impact analysis of pneumococcal conjugate vaccines in Colombia

Jorge Gomez1, Luz Elena Moreno2, Dagna Constenla3

  • 1GSK Vaccines, Health Outcomes, Buenos Aires, Argentina.

Expert Review of Pharmacoeconomics & Outcomes Research
|November 30, 2020
PubMed

Insights

Pneumococcal conjugate vaccines (PCVs) in Colombia

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics

Background:

  • Pneumococcal diseases pose a significant public health challenge.
  • Invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) contribute to this burden.
  • The National Immunization Program (NIP) in Colombia seeks cost-effective vaccination strategies.

Purpose of the Study:

  • To conduct a budget impact analysis of pneumococcal conjugate vaccines (PCVs) within Colombia's NIP.
  • To compare the costs associated with PHiD-CV and PCV-13 over a 5-year period.
  • To inform vaccine selection under budgetary constraints.

Main Methods:

  • A 5-year budget impact analysis (2020-2024) from a healthcare system perspective.
  • Comparison of direct medical costs with and without PCV vaccination.
  • Utilized published efficacy data and Pan-American Health Organization vaccine prices.
  • Assumed 90% vaccine coverage based on Colombian data.

Main Results:

  • PHiD-CV vaccination in Colombia's NIP could reduce pneumococcal disease treatment costs by US$46.1 million (2020-2024).
  • PCV-13 vaccination could reduce costs by US$40.2 million over the same period.
  • PHiD-CV has a lower budget impact (US$100.1 million) and annual vaccine dose cost compared to PCV-13 (US$121.4 million).

Conclusions:

  • PHiD-CV offers a potentially more cost-effective option for Colombia's NIP.
  • The findings support informed vaccine selection for national immunization programs facing budget limitations.
  • Budgetary constraints can be managed effectively through strategic PCV implementation.

Keywords:
13-valent pneumococcal conjugate vaccineBudget impact analysiscolombiapneumococcal conjugate vaccinationpneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.0K
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

12.9K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
603
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.0K
Vaccinations01:51

Vaccinations

Overview
49.6K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
299
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
559
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
334